article thumbnail

Development of Generic Drug Products by Pharmaceutical Industries Considering Regulatory Aspects: A Review

Drug Patent Watch

International License Abstract Development of generic drug product…. The post Development of Generic Drug Products by Pharmaceutical Industries Considering Regulatory Aspects: A Review appeared first on DrugPatentWatch - Make Better Decisions. This paper was originally published by Md.

article thumbnail

In the News: October Regulatory and Development Updates

Camargo

Unpacking the (Black) Box: Antares Licenses Urology Product with Boxed Warning. When the FDA requires a product’s labeling to include a boxed warning (also called a “black box warning” because the text is surrounded by black border), the potential market value of the drug often drops severely.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Development of the generic drug industry in the US after the Hatch-Waxman Act of 1984

Drug Patent Watch

This article was originally published by Garth Boehm, Lixin Yao, Liang Hana, and Qiang Zheng in Acta Pharmaceutica Sinica under a creative commons license. The post Development of the generic drug industry in the US after the Hatch-Waxman Act of 1984 appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Should we be worried about pharma’s supply chain?

World of DTC Marketing

We can’t continue to develop drugs the same way as we have done before. A blood-thinning agent, heparin, had been adulterated due to the product license holder (Baxter) procuring a toxic substance that had been illegally substituted for the genuine registered material.

article thumbnail

Pharma Pulse 1/15/25: PBMs Mark Up Specialty Generic Drugs, Flurry of Acquisitions/Licensing Deals Amid JPM25 & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

article thumbnail

Brexit fallout continues with batch testing concerns

Pharmaceutical Technology

Even following the Brexit vote, the EU remains the UK’s largest trading partner, and a high proportion of UK drugs originate from European countries. Historically, EU imports have made up around two-thirds of NHS supply, with 80-90% of generic drugs sourced from outside the UK.

Medicine 290
article thumbnail

A Short-Term Gain for a Long-Term Loss? The Build Back Better Act’s Medicare Drug Price Negotiation Program Ignores Hatch-Waxman/BPCIA Realities. and that May Mean Big Bad Business for Generic Drug/Biosimilar Manufacturers

FDA Law Blog

139001 lays out a process by which the Secretary would: Identify “negotiation-eligible drugs” from among qualifying single-source drugs that are among the top 50 with the highest Part D spending, the top 50 with the highest Part B spending, and insulins. 5376 because the price of the brand-name drug/biologic may have been cut by 60%.